Duraphat’s medicine licence puts caries control back on regulatory ground
Duraphat fluoride varnish sits in a different regulatory category from the many fluoride varnishes that dental teams encounter in practice. Colgate presents it as the only fluoride varnish on the UK market with legal status as a medicine and a product licence for caries control, a distinction that matters when prevention is being delivered under a formal prescribing framework rather than as a generic preventive coating.
For clinicians, the point is not simply semantic. The MHRA defines a medicine as a substance or combination of substances presented as having properties for treating or preventing disease in people, while a medical device’s principal mode of action does not include treating or preventing disease. In the context of fluoride varnish, that regulatory split determines how a product can be described, how it is positioned for use, and which members of the dental team can supply or administer it within their scope of practice.
Caries prevention depends on consistent, repeated fluoride exposure at the right concentration and interval. A varnish licensed for disease prevention aligns more cleanly with that model than a product intended primarily for hypersensitivity relief. The clinical consequence is straightforward: when a team chooses a varnish for caries management, the intended mechanism, the licence, and the documentation should all point in the same direction.
Licensed indications and the preventive pathway
The product information for Duraphat lists prevention of caries in children and adults as part of a comprehensive control programme, prevention of recurring or marginal caries, prevention of progression of caries, prevention of decalcification around orthodontic appliances, and prevention of pit and fissure occlusal caries. Those indications place the varnish squarely inside established preventive dentistry rather than in the narrower territory of symptom relief.
Current prevention guidance recommends 22,600 ppm fluoride varnish twice a year for children aged three years and over, rising to three-monthly applications for patients at increased caries risk. For adults at increased risk, applications may be recommended every three or six months depending on the caries pathway. In practical terms, that means the varnish is not a one-off adjunct; it is part of a scheduled preventive programme that depends on risk stratification, recall discipline, and repeated reinforcement of home-care measures.
A quick application schedule may sound routine, but the regulatory status changes the clinical stakes. When a product is licensed for caries control, it supports the prescriber’s responsibility to match indication, age, risk level, and administration protocol with a product that is specifically authorised for that purpose. It also matters for appropriately trained extended duties dental nurses and for dental hygienists and dental therapists working to exemptions, where scope and product status must be clear before treatment starts.
Why the label matters at the chairside
One sentence cuts through the confusion: not every fluoride varnish marketed to dental teams is licensed to prevent caries.
That distinction becomes visible in everyday practice, especially when products carry child-friendly flavours or presentation features that can make them look interchangeable. Colgate argues that some non-licensed fluoride varnishes on the UK market are intended for hypersensitive teeth rather than caries control, and that flavouring alone should not be taken as evidence of a preventive indication. The practical risk is obvious: a product designed around comfort or aesthetics can be mistaken for one authorised to prevent disease.
Preventive dentistry has always relied on accurate product selection. Fluoride varnish is not just a material to be painted on teeth; it is part of a pharmacological prevention strategy. The varnish’s role is to deliver fluoride at a level and frequency that supports enamel remineralisation, reduces demineralisation, and helps interrupt the progression of early carious change. When used around orthodontic appliances, on occlusal surfaces, or in patients with recurring caries, the clinical rationale is anchored in the same pathway: fluoride shifts the balance away from mineral loss and toward repair.
Transparent product information and informed choice
Colgate says the product licence information for Duraphat is publicly accessible through the MHRA website, including the Summary of Product Characteristics. For dental professionals, that document is more than administrative paperwork. It is the clearest source for the authorised indications, age restrictions, and practical details that should shape consent and application.
Before application, patients, parents, or carers should be told why the varnish is being used, what benefits are expected, how the procedure is carried out, what side effects may occur, and what alternatives exist. The procedure itself is described as quick, simple, and painless, applied with a small brush after the patient has eaten. Duraphat has a raspberry taste, and its opaque yellow tint is temporary, fading or able to be brushed off after about four hours if preferred.
For a restless child, the visible tint can serve as a useful application guide. For the clinician, it offers a way to verify coverage across the relevant tooth surfaces without prolonging the appointment. The tint is a practical feature, not a therapeutic one, but in busy preventive clinics, practical features can help the treatment land more reliably.
Adult caries risk is becoming harder to ignore
The conversation around fluoride varnish often focuses on children, yet adult caries risk is taking up more space in service planning. Planned caries pathways for higher-risk adults are being aligned with wider dental reform and the 10-year NHS plan, which places more weight on prevention and stratified pathways of care. In that setting, licensed caries-control products matter because adult prevention is increasingly being organised as a repeatable, documentable intervention rather than an informal add-on to routine hygiene visits.
Flavoured varnishes marketed for children can create an unintended signal that the product is meant to be child-specific or universally interchangeable. The evidence cited here points in a different direction. A review of flavoured fluoride varnishes found that flavour alone was not an effective way to engage a child, while simple choices such as safety glasses or deciding which side of the arch to start on were more effective ways to give the child some control. Engagement, then, comes less from taste than from predictable, respectful chairside behaviour.
Prescribing clarity is the real benefit
Duraphat’s main value in this discussion is regulatory clarity. A varnish licensed for caries control gives dental teams a product whose indication, concentration, and use case are aligned with preventive dentistry rather than borrowed from another purpose. In a setting where fluoride varnish is used at set intervals for risk-based prevention, that alignment reduces ambiguity at the point of prescribing and administration.
The remaining issue is not whether fluoride varnish works as a preventive concept. The more immediate question is whether the product being used is authorised for the disease process being treated, and whether the patient’s age, risk profile, and care pathway match the product licence. For caries prevention, those details are not administrative footnotes; they are the basis of defensible, routine practice.